|
|
|
|
|
|
|
SIZE:
|
|
|
|
GENERIC NAME:
|
|
|
|
MANUFACTURER:
|
|
|
|
UNIT:
|
|
|
|
ADMINISTRATION ROUTE:
|
|
|
|
FDA PREGNANCY GROUP:
|
|
C
|
|
INDICATIONS:
|
|
Deficiency, vitamin K |
|
Hemorrhagic disease of the newborn |
|
Hypoprothrombinemia |
|
Toxicity, coumarin |
| |
|
|
SIDE EFFECTS:
|
|
anaphylactic shock |
|
anaphylactoid reactions |
|
bronchospasm |
|
cardiac arrest |
|
cyanosis |
|
diaphoresis |
|
dizziness |
|
dysgeusia |
|
dyspnea |
|
erythema |
|
flushing |
|
hemolysis |
|
hyperbilirubinemia |
|
hypotension |
|
injection site reaction |
|
jaundice |
|
pruritus |
|
respiratory arrest |
|
|
ABSOLUTE
CONTRAINDICATIONS :
|
|
|
|
RELATIVE
CONTRAINDICATIONS : |
|
anticoagulant therapy |
|
biliary tract disease |
|
breast-feeding |
|
children |
|
hepatic disease |
|
hypoprothrombinemia |
|
intramuscular administration |
|
intravenous administration |
|
jaundice |
|
neonates |
|
pregnancy |
|
|
ADULT DOSE:
|
|
Hypoprothrombinemia, anticoagulant-induced (coumarin- or indanedione-derivative)-
Intramuscular or subcutaneous, 2.5 to 10 mg, or up to 25 mg (rarely up to 50 mg) ; may be repeated after six to eight hours if necessary; subsequent doses should be determined by prothrombin time (PT) response and/or clinical condition .
Hypoprothrombinemia due to other causes-
Intramuscular or subcutaneous, 2.5 to 25 mg or more (rarely up to 50 mg) ; the amount administered depends on the severity of the condition and the clinical and/or PT response obtained .
Prevention of hypoprothrombinemia during prolonged total parenteral nutrition-
Intramuscular, 5 to 10 mg once a week . |
|
MAXIMUM ADULT DOSE:
|
|
|
|
PEDIATRIC DOSE:
|
|
Infants receiving unfortified milk substitutes or who are exclusively breast-fed-
Intramuscular or subcutaneous, 1 mg per month if vitamin K content of diet is less than 0.1 mg per L.
Prevention of hypoprothrombinemia during prolonged total parenteral nutrition-
Intramuscular, 2 to 5 mg once a week .
Treatment of hypoprothrombinemia, anticoagulant-induced (coumarin- or indanedione-derivative)-
Infants-Intramuscular or subcutaneous, 1 to 2 mg; may be repeated in four to eight hours .
Children-Intramuscular or subcutaneous, 2.5 to 10 mg; may be repeated in six to eight hours .
Treatment of hypoprothrombinemia due to other causes-
Infants-Intramuscular or subcutaneous, 2 mg .
Children-Intramuscular or subcutaneous, 5 to 10 mg .
Hemorrhagic disease of the newborn-
Prophylaxis-Intramuscular, 0.5 to 1 mg within one hour of birth ; may be repeated after six to eight hours if necessary (e.g., if mothers received anticonvulsants during pregnancy).
Treatment-Intramuscular or subcutaneous, 1 mg ; higher doses may be required for infants whose mothers received oral anticoagulants or anticonvulsants during pregnancy .
Note: The parenteral dosage form of phytonadione contains benzyl alcohol, which is not recommended for use in neonates. However, the small amount of benzyl alcohol contained in these preparations, when used as directed, has not been shown to cause toxicity . |
|
MAXIMUM PEDIATRIC
DOSE:
|
|
|
|
ELDERLY DOSE:
|
|
|
|
|
|
|
|